Drug Approval | April 20, 2026
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The investment case for health technology in India is frequently overstated in one direction and understated in another
Muted movement reflects consolidation phase as investors await earnings triggers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
